Wells Fargo analyst Jim Birchenough upgraded Sunesis Pharmaceuticals to Outperform following a review of updated data for novel BTK inhibitor vecabrutinib at the American Society of Hematology meeting. Expert feedback at the meeting suggests vecabrutinib could become treatment of choice for Imbruvica resistance and ultimately a preferred choice over Imbruvica as a frontline treatment in a $3B-plus BTK inhibitor market, Birchenough tells investors in a research note. The analyst expects positive vecabrutinib data despite recent management departures and upped his price target for Sunesis shares to $8 from $2.